Journal of Clinical Virology - Volume 82 - Supplement 1 - September 2016

98 / 152

S94 Abstracts / Journal of Clinical Virology 82S (2016) S1–S142
Abstract no: 347
Presentation at ESCV 2016: Poster 147
The Alere HIV Combo point-of-care test; Useful
in clinical practice?
Carla van Tienen ∗, Sharona Rugebregt ,
Sandra Scherbeijn , Corine Geurts van Kessel ,
Hannelore Götz
1 Erasmus Medical Centre, The Netherlands
2 Rotterdam-Rijnmond Public Health Service, The
Netherlands
Introduction: The Alere® HIV-1/2 Ag/Ab Combo point-of-care-
test (POCT) is a commercially available 4th generationpoint-of-care
test for the diagnosis of HIV infection, which allows for detection of
acute infection. We evaluated the sensitivity in patients with acute
and chronic HIV-1 infection using 95 samples.
Methods: A validation of a point-of-care test using 95 serum
samples collected in 2008–2016 and that were stored at −80 ◦C.
Twenty-four samples were only p24 positive; 49 samples were
both antibody and p24 positive; 17 samples were only antibody
positive and 5 samples were HIV negative. The majority of the sam-
ples came from patients attending an outpatient clinic for sexually
transmitted diseases in Rotterdam, The Netherlands.
Results: The 90 HIV-1 positive samples were confirmed by the
LiasonXL Ag/ab combo assay or the Abbott Architect and West-
ern Blot (in case of antibody positivity), and by PCR or the VIDAS
quantitative HIV p24 assay in case of p24 positivity.
The overall sensitivity for diagnosing HIV infection of the Alere
test was 91% (82/90) and the specificitywas 100% (5/5). Considering
the p24 only positive samples, the sensitivity of the Alere test was
63% (15/24).When both antibody and antigen testingwere positive,
the sensitivity for picking up p24 with the Alere was 22% (11/49),
but the antibody component was positive in all samples (49/49).
Conclusion: In a laboratory setting, theAlere® test has anoverall
sensitivity of 91% to pick up any type of HIV-1 infection. The sensi-
tivity for the diagnosis of acute infection lies between 22% and 63%.
We conclude that the test has improved detection of acute infec-
tion compared to previous 4G POCT. It performs relatively well in
detecting early acuteHIVpatients andmay be beneficial as an initial
screening in patients with a recent exposure to HIV.
Abstract no: 60
Presentation at ESCV 2016: Poster 148
Prevalence of human papilloma virus in
HIV-positive patients: A preliminary study
Tugba Bozdemir ∗, Candan Cicek , Ugur Onal ,
Deniz Gokengin re Altuglu
1 Ege University, Faculty of Medicine, Department of
Medical Microbiology, Izmir, Turkey
2 Ege University, Faculty of Medicine, Department of
Infectious Diseases, Izmir, Turkey
Objectives: Human papilloma virus (HPV) is an oncogenic virus
and some types are the main cause of cervical cancer. HPV types
are divided into three main groups on the basis of their epidemi-
ological association with cervical and penile cancer. Fifteen HPV
types were classified as high-risk types (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68, 73, and 82); three were classified as probable
high-risk types (26, 53, and 66); and 11 were classified as low-risk
types (6, 11, 40, 42, 43, 44, 53, 54, 61, 70, and 72) Data on
Table 1
Human papillomavirus types in HIV-positive patients.
HPV type Infections with one
HPV type
HPV types Infections with
multiple HPV types
Female (n) Male (n) Female (n) Male ( n)
1 1 d 5 1
1 1 2 1 d others
(3
1
3 1 1 1 d others
(3
6
1
3 1 1 d others
(4
1
4 1 1 d others
(
4
6
1
4 1 4 nd 4 1
5 1 2 4 nd 5 1
5 1 5 d others
(1
1
7 1 5 nd others
(1
1
6 nd 6 1
6 d others
(1
1
6 d others
(
1
a High risk types.
b Probable high risk types.
c Low-risk types.
HPV prevalence among HIV-infected people in Turkey is limited. In
this study, we aimed to investigate HPV prevalence in HIV-positive
patients without symptoms of any sexually transmitted diseases.
Methods: Between September 2015 and April 2016, vaginal and
urethral swab specimens were self-collected from 80 [71 (88.8%)
male, 9 (11.2%) female] HIV positive patients. The age range of
patients is between 20 to 69 years (median: 34 years). Nucleic acid
was extracted (Ribospin vRDviral RNA/DNAExtractionKit, GeneAll,
Seegene, South Korea) according to the manufacturer’s protocol.
Amplification of nucleic acid was performed using DPO primers
and Anyplex II HPV28 Detection kit (Seegene, South Korea). PCR
products were detected by real-time PCR on BioRad.
Results: Of the 80 patients, 26 (32.5%) were positive and
54 (67.5%) were negative for HPV. Human papilloma virus was
detected in 5 (5/9, 55.5%) female patients and 21 (21/71, 29.6%)
male patients. More than one human papillomavirus serotypes
were detected in 12 out of 26 positive patients. Overall, 21 different
serotypes were detected The most common HPV types in
patients were 16, 42, 53, 54 and 68. Of the 14 patients infected
with one HPV type, nine were high-risk and five were low-risk
types. Most of the patients with multiple HPV types were infected
with high-risk HPV types. Overall, 18 (69.2%) patients were found
to be infected with high-risk HPV types. HPV positive patients were
referred to the clinic for follow up.
Conclusion: HPV infection seems to be an important sexually
transmitted disease in HIV positive patients presenting to our hos-
pital and should be screened for even in asymptomatic patients.
Reference
[1] N. Munoz, F.X. Bosch, S. de Sanjose, et al., Epidemiologic classification of
human papillomavirus types associated with cervical cancer, N. Engl. J. Med.
348 (2003) 518–527.
[2] M. Schmitt, B. Dondog, T. Waterboer, et al., Abundance of multiple high-risk
human papillomavirus (HPV) infections found in cervical cells analyzed by use
of an ultrasensitive HPV genotyping assay, J. Clin. Microbiol. 48 (1) (2010)
143–149.